Wakasugi M, Kazama JJ, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Narita I (2013) Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab 31:315–321. https://doi.org/10.1007/s00774-012-0411-z

Article  PubMed  Google Scholar 

Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C (2000) Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396–399. https://doi.org/10.1046/j.1523-1755.2000.00178.x

Article  CAS  PubMed  Google Scholar 

Coco M, Rush H (2000) Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115–1121. https://doi.org/10.1053/ajkd.2000.19812

Article  CAS  PubMed  Google Scholar 

Tentori F, McCullough K, Kilpatrick RD, Bradbury BD, Robinson BM, Kerr PG, Pisoni RL (2014) High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 85:166–173. https://doi.org/10.1038/ki.2013.279

Article  PubMed  Google Scholar 

Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, Andreucci VE, Fukagawa M, Frimat L, Mendelssohn DC, Port FK, Pisoni RL, Robinson BM (2015) Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol: CJASN 10:98–109. https://doi.org/10.2215/CJN.12941213

Article  CAS  PubMed  Google Scholar 

Taniguchi M, Fukagawa M, Fujii N, Hamano T, Shoji T, Yokoyama K, Nakai S, Shigematsu T, Iseki K, Tsubakihara Y, Committee of Renal Data Registry of the Japanese Society for Dialysis T (2013) Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Ther Apher Dial: Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jan Soc Dial Ther 17:228. https://doi.org/10.1111/1744-9987.12030

Article  CAS  Google Scholar 

Block GA, Kilpatrick RD, Lowe KA, Wang W, Danese MD (2013) CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol: CJASN 8:2132–2140. https://doi.org/10.2215/CJN.04260413

Article  PubMed  PubMed Central  Google Scholar 

Fernandez-Martin JL, Martinez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G, Locatelli F, Gorriz JL, Rutkowski B, Ferreira A, Bos WJ, Covic A, Rodriguez-Garcia M, Sanchez JE, Rodriguez-Puyol D, Cannata-Andia JB, group C, (2015) Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol, Dial, Transplant : Off Publ Eur Dial Transplant Assoc - Eur Ren Assoc 30:1542–1551. https://doi.org/10.1093/ndt/gfv099

Article  CAS  Google Scholar 

Wakasugi M, Kazama JJ, Kikuchi K, Yasuda K, Wada A, Hamano T, Masakane I, Narita I (2019) Hemodialysis product and hip fracture in hemodialysis patients: a nationwide cohort study in Japan. Ther Apher Dial: Off Peer-Rev J Int Soc Apher, Jpn Soc Apher, Jpn Society Dial Ther 23:507–517. https://doi.org/10.1111/1744-9987.12807

Article  CAS  Google Scholar 

Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70:1358–1366. https://doi.org/10.1038/sj.ki.5001754

Article  CAS  PubMed  Google Scholar 

Custodio MR, Koike MK, Neves KR, dos Reis LM, Graciolli FG, Neves CL, Batista DG, Magalhaes AO, Hawlitschek P, Oliveira IB, Dominguez WV, Moyses RM, Jorgetti V (2012) Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrol, Dial, Transplant: Off Publ Eur Dial Transplant Assoc – Eur Ren Assoc 27:1437–1445. https://doi.org/10.1093/ndt/gfr447

Article  CAS  Google Scholar 

Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516–1525. https://doi.org/10.1056/NEJMoa031633

Article  CAS  PubMed  Google Scholar 

Investigators ET, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367:2482–2494. https://doi.org/10.1056/NEJMoa1205624

Article  Google Scholar 

Diaz-Tocados JM, Rodriguez-Ortiz ME, Almaden Y, Pineda C, Martinez-Moreno JM et al (2019) Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney Int 95:1064–1078. https://doi.org/10.1016/j.kint.2018.12.015

Article  CAS  PubMed  Google Scholar 

Koiwa F, Tokunaga S, Asada S, Endo Y, Fukagawa M, Akizawa T (2021) Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients. Kidney Int Rep 6:2830–2839. https://doi.org/10.1016/j.ekir.2021.08.020

Article  PubMed  PubMed Central  Google Scholar 

Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM (2017) Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA 317:156–164. https://doi.org/10.1001/jama.2016.19468

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71

Article  PubMed  PubMed Central  Google Scholar 

Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drueke TB, Evaluation of Cinacalcet HTtLCETI (2015) Effects of cinacalcet on fracture events in patients receiving hemodialysis: the evolve trial. J Am Soc Nephrol 26:1466–1475. https://doi.org/10.1681/ASN.2014040414

Article  CAS  PubMed  Google Scholar 

Kazama JJ, Koiwa F, Yokoyama K, Fukagawa M, Asano K, Honda D, Akizawa T (2022) First-in-patient phase i/ii study of upacicalcet in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: pharmacokinetic and pharmacodynamic properties. Clin Pharmacokinet 61:1271–1284. https://doi.org/10.1007/s40262-022-01139-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cunningham J, Danese M, Olson K, Klassen P, Chertow GM (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793–1800. https://doi.org/10.1111/j.1523-1755.2005.00596.x

Article  CAS  PubMed  Google Scholar 

Block GA, Chertow GM, Sullivan JT, Deng H, Mather O, Tomlin H, Serenko M (2019) An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. PLoS ONE 14:e0213774. https://doi.org/10.1371/journal.pone.0213774

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shigematsu T, Koiwa F, Isaka Y, Fukagawa M, Hagita K, Watanabe YS, Honda D, Akizawa T (2023) Efficacy and safety of upacicalcet in hemodialysis patients with secondary hyperparathyroidism: a randomized placebo-controlled trial. Clin J Am Soc Nephrol : CJASN 18:1300–1309. https://doi.org/10.2215/CJN.0000000000000253

Article  PubMed  Google Scholar 

Itano Y, Kato S, Tsuboi M, Kasuga H, Tsuruta Y, Sato F, Hishida M, Ishimoto T, Kosugi T, Ando M, Kuwatsuka Y, Maruyama S (2020) A prospective, randomized clinical trial of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism (the DUET trial). Kidney Int Rep 5:2168–2177. https://doi.org/10.1016/j.ekir.2020.09.010

Article  PubMed  PubMed Central  Google Scholar 

El-Shafey EM, Alsahow AE, Alsaran K, Sabry AA, Atia M (2011) Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial: Off Peer-Rev J Int Soc Apher, Jpn Soc Apher, Jpn Soc Dial Ther 15:547–555. https://doi.org/10.1111/j.1744-9987.2011.00994.x

Article  CAS  Google Scholar 

Yeung WG, Palmer SC, Strippoli GFM, Talbot B, Shah N, Hawley CM, Toussaint ND, Badve SV (2023) Vitamin D therapy in adults with ckd: a systematic review and meta-analysis. Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2023.04.003

Article  PubMed  Google Scholar 

Komaba H, Zhao J, Karaboyas A, Yamamoto S, Dasgupta I, Hassan M, Zuo L, Christensson A, Combe C, Robinson BM, Fukagawa M (2023) Active vitamin D use and fractures in hemodialysis patients: results from the international DOPPS. J Bone Miner Res: Off J Am Soc Bone Miner Res 38:1577–1585. https://doi.org/10.1002/jbmr.4913

Article  CAS  Google Scholar